MedTrace Logo

Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis

NCT05133453 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-08-30

No results posted yet for this study

Summary

This study aims at determining the the efficiency and prognosis of using pirfenidone drug among asbestosis patients.

Conditions

  • Asbestosis

Interventions

DRUG

Pirfenidone

drug intake three times daily for one year

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Marwa M Fouad, MD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2025-02-28
Completion
2026-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05133453 on ClinicalTrials.gov